Compounds > isoxepac
Page last updated: 2024-12-06

isoxepac

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Isoxepac is a non-steroidal anti-inflammatory drug (NSAID) that was initially developed as a potential treatment for rheumatoid arthritis. It is a derivative of phenylbutazone and has similar pharmacological properties, including analgesic, anti-inflammatory, and antipyretic effects. Isoxepac inhibits the production of prostaglandins, which are involved in pain and inflammation. Despite initial promise, clinical trials indicated that isoxepac had a high risk of gastrointestinal side effects, limiting its widespread use. Research into isoxepac focused on understanding its mechanism of action, identifying potential alternative drug formulations, and exploring its potential applications in other areas, such as the treatment of cancer pain. While isoxepac is no longer commercially available, research continues to explore its potential therapeutic benefits in various applications.'

isoxepac: orally effective non-steroidal anti-inflammatory agent with moderate analgesic & antipyretic activity; structure in first three sources [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID41448
CHEMBL ID33211
CHEBI ID135102
SCHEMBL ID24970
MeSH IDM0063776

Synonyms (74)

Synonym
AC-4725
dibenz[b,e]oxepin-2-acetic acid, 6,11-dihydro-11-oxo-
2-(11-oxo-6h-benzo[c][1]benzoxepin-2-yl)acetic acid
11-oxo-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid
isoxepacum [inn-latin]
6,11-dihydro-11-oxodibenz(b,e)oxepin-2-acetic acid
dibenz(b,e)oxepin-2-acetic acid, 6,11-dihydro-11-oxo-
brn 1320243
artil
nsc 300907
nsc300907
p 720549
isoxepac
hp 549
55453-87-7
dibenz[b, 6,11-dihydro-11-oxo-
6,e]oxepin-2-acetic acid
nsc-300907
D04638
artil (tn)
isoxepac (usan/inn)
hp-549
p-549
hp-720549
CHEBI:135102
CHEMBL33211
p-720549
2-(11-oxo-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid
A830652
nd4-b2
6,11-dihydro-11-oxo-dibenz[b,e]oxepin-2-acetic acid
(11-oxo-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid
6,11-hydro-11-oxo-dibenz[b,e]oxepin-2-acetic acid
isoxepacum
5-18-08-00457 (beilstein handbook reference)
unii-2kh283q0z5
isoxepac [usan:inn:ban]
2kh283q0z5 ,
FT-0630680
AB05479
AKOS015895231
S5044
D4242
6,11-dihydro-11-oxodibenzo[b,e]oxepin-2-acetic acid
6h-11-oxodibenzo[b,e]oxepin-2-acetic acid
SCHEMBL24970
NCGC00253693-01
dtxsid8057772 ,
cas-55453-87-7
dtxcid9031561
tox21_113815
6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid
isoxepac [mi]
isoxepac [usan]
isoxepac [inn]
6,11-dihydro-11-oxodibenz[b,e]oxepin-2-yl acetic acid
QFGMXJOBTNZHEL-UHFFFAOYSA-N
TS-03511
2-{2-oxo-9-oxatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-5-yl}acetic acid
Q-100635
(11-oxo-6,11-dihydro-dibenzo[b,e]oxepin-2-yl)-acetic acid
mfcd00242952
(11-oxo-6,11-dihydrodibenzo[b,e]oxepin-2-yl)acetic acid (isoxepac)
CS-0031651
BCP12544
CCG-267128
Q27254870
2-(11-oxo-6,11-dihydrodibenzo-[b,e]oxepin-2-yl)acetic acid
EN300-18552809
2-{2-oxo-9-oxatricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-5-yl}acetic acid
HY-W050088
2-(11-oxo-6,11-dihydrodibenzo[b,e]oxepin-2-yl)aceticacid
SY051246
Z2681893145
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dibenzooxazepineAn organic heterotricyclic compound consisting of two benzene rings fused to a seven-membered ring containing one oxygen and one nitrogen atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency30.90080.007215.758889.3584AID1224835
RAR-related orphan receptor gammaMus musculus (house mouse)Potency19.39160.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency21.31380.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency21.31380.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency16.08340.000714.592883.7951AID1259369; AID1259392
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency31.67040.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency29.84930.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency10.68220.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency28.17960.001530.607315,848.9004AID1259401
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency2.66010.023723.228263.5986AID743222
activating transcription factor 6Homo sapiens (human)Potency26.83250.143427.612159.8106AID1159516
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (57)

Assay IDTitleYearJournalArticle
AID1150274Toxicity in po dosed rat assessed as induction of gastric lesion1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1150270Analgesic activity in po dosed mouse assessed as inhibition of acetic acid-induced writhing1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1149356Therapeutic ratio of ID50 for ulcerogenicity in Wistar rat to ED50 for antiinflammatory activity against Mycobacterium butyricum adjuvant-induced polyarthritis in Lewis albino rat non-injected paw1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 1. 6,11-Dihydro-11-oxodibenz]b,e]oxepin-2-acetic acids.
AID1133922Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 2. Dihydro-10-oxofuro-and -thieno[3,2-c][1]benzoxepin-8-acetic acids.
AID1150260Antiinflammatory activity in Wistar albino rat assessed as inhibition of adjuvant-induced arthritis at 10 mg/kg, po administered for 14 days prior to adjuvant challenge relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1149352Analgesic activity in po dosed CD-1 mouse assessed as inhibition of phenylquinone-induced writhing administered prior to phenylquinone challenge measured 5 mins after phenylquinone injection1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 1. 6,11-Dihydro-11-oxodibenz]b,e]oxepin-2-acetic acids.
AID1150259Antiinflammatory activity in rat with prolonged phase of inflammation assessed as inhibition of adjuvant-carrageenan-induced paw edema at 2 mg/kg, po relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1149353Antiinflammatory activity against Mycobacterium butyricum adjuvant-induced polyarthritis in po dosed Lewis albino rat assessed as decrease in adjuvant treated paw edema administered daily for 21 days prior to adjuvant injection1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 1. 6,11-Dihydro-11-oxodibenz]b,e]oxepin-2-acetic acids.
AID1150265Antiinflammatory activity in Wistar albino rat assessed as inhibition of adjuvant-induced arthritis at 10 mg/kg, po administered for 14 days followed by adjuvant challenge relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1149354Antiinflammatory activity against Mycobacterium butyricum adjuvant-induced polyarthritis in po dosed Lewis albino rat assessed as decrease in non-injected paw edema administered daily for 21 days prior to adjuvant injection1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 1. 6,11-Dihydro-11-oxodibenz]b,e]oxepin-2-acetic acids.
AID1150001Antiinflammatory activity in po dosed Wistar rat assessed as inhibition of carrageenan-induced paw edema administered 1 hr prior to carrageenan challenge measured after 3 hrs of carrageenan challenge1977Journal of medicinal chemistry, Nov, Volume: 20, Issue:11
Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 3. omega-(6,11-Dihydro-11-oxodibenz[b,e]oxepin-2-yl)alkanoic acids.
AID132251Inhibition of arachidonic acid oedema in mouse ear.1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Dibenzoxepinone hydroxylamines and hydroxamic acids: dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity.
AID1149349Therapeutic ratio of ID50 for ulcerogenicity in Wistar rat to ED50 for antiinflammatory activity against Mycobacterium butyricum adjuvant-induced polyarthritis in Lewis albino rat adjuvant treated paw1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 1. 6,11-Dihydro-11-oxodibenz]b,e]oxepin-2-acetic acids.
AID1133923Gastrointestinal toxicity in po dosed rat assessed as induction of gastric irritation1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 2. Dihydro-10-oxofuro-and -thieno[3,2-c][1]benzoxepin-8-acetic acids.
AID1150257Antiinflammatory activity in rat with acute phase of inflammation assessed as inhibition of adjuvant-carrageenan-induced paw edema at 2 mg/kg, po relative to control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1133924Therapeutic index, ratio of ID50 for po dosed rat to ED50 for po dosed rat1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 2. Dihydro-10-oxofuro-and -thieno[3,2-c][1]benzoxepin-8-acetic acids.
AID1132865Antiinflammatory activity in po dosed Donryu rat assessed as inhibition of carrageenan-induced paw edema1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Nonsteroidal antiinflammatory agents. 2. Derivatives/analogues of dibenz[b,e]oxepin-3-acetic acid.
AID6804Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Dibenzoxepinone hydroxylamines and hydroxamic acids: dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity.
AID1149350Antiinflammatory activity in po dosed Wistar rat assessed as inhibition of carrageenan-induced paw edema administered 1 hr prior to carrageenan challenge measured 3 hrs post-carrageenan injection1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 1. 6,11-Dihydro-11-oxodibenz]b,e]oxepin-2-acetic acids.
AID1150252Antiinflammatory activity in po dosed rat assessed as inhibition of carrageenan-induced paw edema1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1150271Analgesic activity in carrageenan-treated po dosed rat assessed as concentration required to double pain index of control1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1150275Acute toxicity in po dosed rat after 7 days1976Journal of medicinal chemistry, Jul, Volume: 19, Issue:7
6,11-Dihydro-11-oxodibenz [b,e] oxepinacetic acids with potent antiinflammatory activity.
AID1149355Ulcerogenicity in po dosed Wistar rat assessed as induction of gastric irritation1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Dibenz[b,e]oxepinalkanoic acids as nonsteroidal antiinflammatory agents. 1. 6,11-Dihydro-11-oxodibenz]b,e]oxepin-2-acetic acids.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (26)

TimeframeStudies, This Drug (%)All Drugs %
pre-199016 (61.54)18.7374
1990's2 (7.69)18.2507
2000's0 (0.00)29.6817
2010's2 (7.69)24.3611
2020's6 (23.08)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 27.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index27.93 (24.57)
Research Supply Index3.47 (2.92)
Research Growth Index4.21 (4.65)
Search Engine Demand Index34.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (27.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (14.81%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other23 (85.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
aspirin
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.		5.1843benzoic acids;
phenyl acetates;
salicylates		anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent
flurbiprofen
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.		1.9610fluorobiphenyl;
monocarboxylic acid		antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug
ibuprofen
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine		1.9910monocarboxylic acidantipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic
indomethacin
Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.		4.9591aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole		analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic
ketoprofen
Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.		1.9510benzophenones;
oxo monocarboxylic acid		antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic
masoprocol
nordihydroguaretic acid: antioxidant compound found in the creosote bush (Larrea tridentata)		1.9910catechols;
lignan;
tetrol		antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite
phenylbutazone
Phenylbutazone: A butyl-diphenyl-pyrazolidinedione that has anti-inflammatory, antipyretic, and analgesic activities. It has been used in ANKYLOSING SPONDYLITIS; RHEUMATOID ARTHRITIS; and REACTIVE ARTHRITIS.. phenylbutazone : A member of the class of pyrazolidines that is 1,2-diphenylpyrazolidine-3,5-dione carrying a butyl group at the 4-position.		1.9510pyrazolidinesantirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug
phenyl acetate
phenyl acetate: The ester formed between phenol and acetic acid. Don't confuse with phenylacetic acid derivatives listed under PHENYLACETATES.. phenyl acetate : An acetate ester obtained by the formal condensation of phenol with acetic acid.		6.13123benzenes;
phenyl acetates
oxepinac
oxepinac: non-steroidal anti-inflammatory drug; RN given refers to parent cpd; structure in first source & Negwer, 5th ed, #6399		2.3620
ConditionIndicatedRelationship StrengthStudiesTrials
Anasarca
[description not available]		03.260
Gastric Ulcer
[description not available]		02.3620
Edema
Abnormal fluid accumulation in TISSUES or body cavities. Most cases of edema are present under the SKIN in SUBCUTANEOUS TISSUE.		03.260
Stomach Ulcer
Ulceration of the GASTRIC MUCOSA due to contact with GASTRIC JUICE. It is often associated with HELICOBACTER PYLORI infection or consumption of nonsteroidal anti-inflammatory drugs (NSAIDS).		02.3620
Polyarthritis
[description not available]		01.9510
Arthritis
Acute or chronic inflammation of JOINTS.		01.9510
Rheumatoid Arthritis
[description not available]		09.8242
Muscle Spasm
[description not available]		01.9510
Arthritis, Rheumatoid
A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.		04.8242
Spasm
An involuntary contraction of a muscle or group of muscles. Spasms may involve SKELETAL MUSCLE or SMOOTH MUSCLE.		01.9510
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510
Hematochezia
The passage of bright red blood from the rectum. The blood may or may not be mixed with formed stool in the form of blood, blood clots, bloody stool or diarrhea.		01.9610
Gastrointestinal Hemorrhage
Bleeding in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM.		01.9610
Gastritis
Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.		03.3411
Cholera Infantum
[description not available]		01.9610
Menstruation, Painful
[description not available]		01.9510
Hypomenorrhea
[description not available]		01.9510
Dysmenorrhea
Painful menstruation.		06.9510
Adjuvant Arthritis
[description not available]		01.9510
Granulomas
[description not available]		01.9510
Granuloma
A relatively small nodular inflammatory lesion containing grouped mononuclear phagocytes, caused by infectious and noninfectious agents.		01.9510